Abstract:Alzheimer's disease (AD) is the most common neurodegenerative disorders now. Amyloid ß-protein (Aß) has been recognized as the leading cause of AD, and Aß oligomer plays an important role in the early stage of AD. Anti-Ab immunotherapy targeting on the Ab peptide has been demonstrated as one promising AD treatment. The active immunization, exploiting Ab42 as an immunogen, was initiated on AD animal model by Schenk in 1999 and then advanced to clinical trials. However, the clinical trial was haunted due to an occurrence of subacute meningoencephalitis in 6% of patients. Th1-biased responses stimulated by T cell epitope in the Ab42 and Th1-promoting adjuvant (QS-21) were ascribed to this side effect. Meanwhile, anti-Ab antibodies produced in those patients have been proved to be effective in slowering rate of cognitive decline. As an alternative, passive immunization approaches have the advantage of safety and efficacy over active immunization approaches. In this report, several strains of monoclonal antibody (MAb) against Aß1-42 oligomer or different truncation of Aß C terminal was established for AD therapeutic research. MAb specific for Aß1-42 oligomer was prepared with the hybridoma technique and purified through protein A affinity chromatography. The specificity, affinity and titers of the MAb were analyzed by ELISA, western blot and immunohistochemistry (IHC). To determine whether Antibodies treatment improves the ability of learning and memory, 8-month-old SAMP8 mice and 6-month-old APPswe/PS1DE9 mice were administered intraperitoneally and weekly with 400 mg A8 or nonspecific mouse IgG (Sigma-Aldrich) for 8 weeks. The Morris water maze (MWM) has been used for studying therapy-related changes in learning and memory in mice. The visible, hidden versions of MWM and prob trial were performed. The latency and distance to find the location that had contained the platform was measured. Data were recorded through an overhead camera linked with the computer to quantification of latency and distance. Mice were tested in a blinded manner, with group balanced for genotype and treatment. Mice were sacrificed 3 days after the final MWM manipulation for biochemical and histological assessment. Through western blot (WB) and immunohistochemistry (IHC), the soluble and insoluble Aß, phosphorylation of tau at 181/231/404 site, mTOR (mammalian target of rapamycin), LC3-I/II (microtubuler associated protein 1 light chain 3, MAP1rLC3, LC3), glial fibrillary acidic protein (GFAP), tubulin and actin were detected. Our results showed that the mice serum titer reached over 1:256,000 after immunization. Two hybridoma cell lines (BJ08 and BJNa) secreting MAb specific for the Aß1-42 oligomer was established after sub-cloning. They displayed much higher affinity to low molecular Aß1-42 oligomer, and showed the ability to bind Aß1-42 oligomer in the brain section of SAMP8 mice and APPswe/PS1DE9 mice. Using them as immunotherapy, we show that learning and memory ability was improved through intraperitoneal administration in SAMP8 mice. The mice that found the platform increased in antibody treated groups and our data showed a significant decrease in latency and distance compared with other groups (P < 0.05) (nonspecific mouse IgG, antibody solution buffer and no-treated SAMP8 or APPswe/PS1DE9 mice). Meanwhile, soluble Aß, phosphorylation of tau and LC3-II has also been inhibited after immunotherapy. In addition, the expression level of mTOR, GFAP, tubulin and actin were also detected with IHC and displayed no differences among these groups. In conclusion, the MAbs specific for Aß1-42 oligomer is developed. Therapeutic monoclonal antibodies against Aß oligomers have the efficacy in reducing soluble Aß, phosphorylation of tau and LC3-II level and ultimately ameliorated the learning and memory ability, which paves the way for further diagnostic and therapeutic research on AD.

Amelioration of Tau Related Pathology with a Novel Anti‐prion Protein Monoclonal Antibody in an AD Mouse Model

Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer's Mouse Model With Tau Pathology

Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-β immunotherapy

Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease

Therapeutic Monoclonal Antibodies Against Abeta Oligomers for Treatment of Alzheimer's Disease

P2-296: Enhanced Proteolysis of Aβ Peptide Reduces Tau Phosphorylation and Neurofibrillary Tangle Formation in APP/tau Transgenic Mice

Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model

Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice

Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer’s Disease

Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models

Selective Targeting and Protection Against Toxic Amyloid‐beta Oligomers by PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency in Alzheimer’s Disease

P-tau217 Correlates with Neurodegeneration in Alzheimer’s Disease, and Targeting P-Tau217 with Immunotherapy Ameliorates Murine Tauopathy

5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy

APNmAb005, an anti‐tau antibody targeting synaptic tau oligomers, in Phase 1 for treatment of Alzheimer’s Disease and primary tauopathies

Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model

Active Beta-Amyloid Immunization Restores Spatial Learning in Pdapp Mice Displaying Very Low Levels of Beta-Amyloid

Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice